TY - GEN AU - García-Carbonero, Rocio AU - Bazan-Peregrino, Miriam AU - Gil-Martín, Marta AU - Álvarez, Rafael AU - Macarulla, Teresa AU - Riesco-Martinez, Maria C AU - Verdaguer, Helena AU - Guillén-Ponce, Carmen AU - Farrera-Sal, Martí AU - Moreno, Rafael AU - Mato-Berciano, Ana AU - Maliandi, Maria Victoria AU - Torres-Manjon, Silvia AU - Costa, Marcel AU - Del Pozo, Natalia AU - Martínez de Villarreal, Jaime AU - Real Arribas, Francisco AU - Vidal, Noemí AU - Capella, Gabriel AU - Alemany, Ramon AU - Blasi, Emma AU - Blasco, Carmen AU - Cascalló, Manel AU - Salazar, Ramon PY - 2022 UR - https://hdl.handle.net/20.500.12105/25196 AB - VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor.... AB - Part I: patients with advanced refractory solid tumors received one single dose of VCN-01. Parts II and III: patients with pancreatic adenocarcinoma received VCN-01 (only in cycle 1) and nab-paclitaxel plus gemcitabine (VCN-concurrent on day 1 in Part... AB - 26% of the patients initially screened were excluded based on high NAbs levels. Sixteen and 12 patients were enrolled in Part I and II, respectively: RP2D were 1×10 viral particles (vp)/patient (Part I), and 3.3×10 vp/patient (Part II). Fourteen... AB - Treatment with VCN-01 is feasible and has an acceptable safety. Encouraging biological and clinical activity was observed when administered in combination with nab-paclitaxel plus gemcitabine to patients with pancreatic adenocarcinoma. AB - NCT02045602. LA - eng PB - BMJ Publishing Group KW - clinical trials as topic KW - gastrointestinal neoplasms KW - oncolytic virotherapy KW - tumor microenvironment TI - Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. TY - research article ER -